Look­ing to get ahead in a packed mi­graine mar­ket, Am­gen touts head-to-head da­ta for Aimovig

A year af­ter Am­gen an­nounced its in­jectable mi­graine pre­ven­tion drug Aimovig proved a bet­ter op­tion than the wide­ly used treat­ment top­i­ra­mate in a head-to-head study, the phar­ma com­pa­ny is rolling out the full da­ta. But will it be enough to com­pete in a packed mar­ket, in­clud­ing new oral op­tions?

In a Phase IV study con­duct­ed by Am­gen’s old part­ner No­var­tis, mi­graine pa­tients in the Aimovig arm showed a sig­nif­i­cant­ly low­er dis­con­tin­u­a­tion rate due to side ef­fects: 10.5% ver­sus 38.9% in the top­i­ra­mate arm (p<0.001), ac­cord­ing to the com­pa­nies. In ad­di­tion, 55.4% of pa­tients in the Aimovig arm achieved at least a 50% re­duc­tion from base­line in their month­ly mi­graine days, com­pared to 31.2% in the top­i­ra­mate group (p<0.001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.